Table 3. Univariate analysis of factors affecting CTC detection in EOC.
| Factors | N | n (%) | χ 2 | P | |
| CTCs positive rate | CTCs negative rate | ||||
| CTC, circulating tumor cell; EOC, epithelial ovarian cancer; *, R0 refers to no residual disease; R1 refers to residual disease with tumors <1 cm; R2 refers to residual disease with tumors ≥1 cm. | |||||
| Age (year) | 0.666 | 0.414 | |||
| ≤55 | 78 | 64 (82.1) | 14 (17.9) | ||
| >55 | 82 | 63 (76.8) | 19 (23.2) | ||
| CA125 (U/mL) | 1.919 | 0.166 | |||
| ≤35 | 39 | 34 (87.2) | 5 (12.8) | ||
| >35 | 121 | 93 (76.9） | 28 (23.1) | ||
| Ascites (mL) | 5.311 | 0.021 | |||
| <500 | 93 | 68 (73.1) | 25 (26.9) | ||
| ≥500 | 67 | 59 (88.1) | 8 (11.9) | ||
| Cytoreductive surgery* | 5.732 | 0.017 | |||
| R0−R1 | 126 | 95 (75.4) | 31 (24.6) | ||
| R2 | 34 | 32 (94.1) | 2 (5.9) | ||
| Staging | 1.194 | 0.275 | |||
| I−II | 55 | 41 (74.5) | 14 (25.5) | ||
| III−IV | 105 | 86 (81.9 ) | 19 (18.1) | ||
| Grading | 0.354 | 0.552 | |||
| 1−2 | 17 | 15 (88.2) | 2 (11.8) | ||
| 3 | 127 | 100 (78.7) | 27 (21.3) | ||
| Lymph node metastasis | 0.023 | 0.880 | |||
| Yes | 60 | 48 (80.0) | 12 (20.0) | ||
| None | 100 | 79 (79.0) | 21 (21.0) | ||
| Normalized CA125 with the course of chemotherapy | 4.323 | 0.038 | |||
| ≤2 | 72 | 50 (69.4 ) | 22 (30.6) | ||
| >2 | 39 | 34 (87.2) | 5 (12.8) | ||
| Chemosensitivity | 1.913 | 0.167 | |||
| Sensitivity | 121 | 93 (76.9) | 28 (23.1) | ||
| Resistance | 33 | 29 (87.9) | 4 (12.1) | ||